Literature DB >> 33614497

Trimodality PET/CT/MRI and Radiotherapy: A Mini-Review.

Pierre Decazes1,2, Pauline Hinault2, Ovidiu Veresezan3, Sébastien Thureau1,2,3, Pierrick Gouel1,2, Pierre Vera1,2.   

Abstract

Computed tomography (CT) has revolutionized external radiotherapy by making it possible to visualize and segment the tumors and the organs at risk in a three-dimensional way. However, if CT is a now a standard, it presents some limitations, notably concerning tumor characterization and delineation. Its association with functional and anatomical images, that are positron emission tomography (PET) and magnetic resonance imaging (MRI), surpasses its limits. This association can be in the form of a trimodality PET/CT/MRI. The objective of this mini-review is to describe the process of performing this PET/CT/MRI trimodality for radiotherapy and its potential clinical applications. Trimodality can be performed in two ways, either a PET/MRI fused to a planning CT (possibly with a pseudo-CT generated from the MRI for the planning), or a PET/CT fused to an MRI and then registered to a planning CT (possibly the CT of PET/CT if calibrated for radiotherapy). These examinations should be performed in the treatment position, and in the second case, a patient transfer system can be used between the PET/CT and MRI to limit movement. If trimodality requires adapted equipment, notably compatible MRI equipment with high-performance dedicated coils, it allows the advantages of the three techniques to be combined with a synergistic effect while limiting their disadvantages when carried out separately. Trimodality is already possible in clinical routine and can have a high clinical impact and good inter-observer agreement, notably for head and neck cancers, brain tumor, prostate cancer, cervical cancer.
Copyright © 2021 Decazes, Hinault, Veresezan, Thureau, Gouel and Vera.

Entities:  

Keywords:  computed tomography; hybrid imaging; magnetic resonance imaging; positron emission tomography; radiotherapy

Year:  2021        PMID: 33614497      PMCID: PMC7890017          DOI: 10.3389/fonc.2020.614008

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  7 in total

1.  Protein Based Biomaterials for Therapeutic and Diagnostic Applications.

Authors:  Stanley Chu; Andrew L Wang; Aparajita Bhattacharya; Jin Kim Montclare
Journal:  Prog Biomed Eng (Bristol)       Date:  2021-10-26

2.  Characterization of positioning uncertainties in PET-CT-MR trimodality solutions for radiotherapy.

Authors:  Pauline Hinault; Isabelle Gardin; Pierrick Gouel; Pierre Decazes; Sebastien Thureau; Ovidiu Veresezan; Henri Souchay; Pierre Vera; David Gensanne
Journal:  J Appl Clin Med Phys       Date:  2022-04-28       Impact factor: 2.243

3.  Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model.

Authors:  Bilgi Kip; Cansu Umran Tunc; Omer Aydin
Journal:  Ultrason Sonochem       Date:  2021-12-29       Impact factor: 7.491

4.  ES-MION-Based Dual-Modality PET/MRI Probes for Acidic Tumor Microenvironment Imaging.

Authors:  Xiuyan Wei; Haitao Zhao; Gang Huang; Jianhua Liu; Weina He; Qingqing Huang
Journal:  ACS Omega       Date:  2022-01-18

5.  Clinical value of MRI, serum SCCA, and CA125 levels in the diagnosis of lymph node metastasis and para-uterine infiltration in cervical cancer.

Authors:  Chao Ran; Jian Sun; Yunhui Qu; Na Long
Journal:  World J Surg Oncol       Date:  2021-12-09       Impact factor: 2.754

6.  PET and CT Image Fusion of Lung Cancer With Siamese Pyramid Fusion Network.

Authors:  Ning Xiao; Wanting Yang; Yan Qiang; Juanjuan Zhao; Rui Hao; Jianhong Lian; Shuo Li
Journal:  Front Med (Lausanne)       Date:  2022-03-31

7.  Application of 3D Visualization Technology in Complex Abdominal Wall Defects.

Authors:  Zhicheng Song; Wenpei Dong; Dongchao Yang; Jianjun Yang; Jugang Wu; Yiping Wang; Yan Gu
Journal:  Int J Gen Med       Date:  2021-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.